Health
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the first results from the open-label extension trial of the Phase 3 GATHER2 study, which demonstrated monthly treatment with IZERVAY™ (avacincaptad pegol intravitreal solution) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) continued to reduce GA lesion growth for up to 3.5 years, with earlier intervention resulting in greater protection of retinal tissue
About this update from Astellas Pharma Inc.
[{"type":"text","content":"In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area ","length":174,"tagName":"p","attribs":{}},{"type":"text","content":"Study results found no new safety signals and no cases of retinal vasculitis or occlusive vasculitis after IZERVAY treatment of up to 3.5 years","length":143,"tagName":"p","attribs":{}},{"type":"text","content":"New U.S. real-world data from more than 10,000 GA patients support safety and tolerability of IZERVAY with low rates of discontinuation and adverse events","length":160,"tagName":"p","attribs":{}},{"type":"text","content":"TOKYO, Oct. 19, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the first results from the open-label extension trial of the Phase 3 GATHER2 study, which demonstrated monthly treatment with IZERVAY™ (avacincaptad pegol intravitreal solution) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) continued to reduce GA lesion growth for up to 3.5 years, with earlier intervention resulting in greater protection of retinal tissue area. IZERVAY was well tolerated, with no cases of retinal vasculitis or occlusive vasculitis. These findings, which indicate a cumulative treatment benefit with IZERVAY, were presented at the American Academy of Ophthalmology 2025 Annual Meeting (AAO 2025) during the Retina Subspeciality Day in Orlando, Fla.","length":857,"tagName":"p"},{"type":"image","alt":"Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.) (PRNewsfoto/Astellas Pharma Inc.)","displaySize":"","headline":null,"caption":"Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.) (PRNewsfoto/Astellas Pharma Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":110,"url":"https://media.zenfs.com/en/prnewswire.com/2ea847d4f0afcbab05cc0666e5cfd53b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gt2H1Ajgjzgw_owZJZe3uA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2ea847d4f0afcbab05cc0666e5cfd53b","width":4...